Logo of Epsilon Healthcare (ASX:EPN)Latest Epsilon Healthcare (ASX:EPN) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Epsilon Healthcare lifts receipts 34% as cash falls below A$1 million

Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
30 Oct 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Epsilon Healthcare Posts Record $3.14M Receipts, Accelerates Growth Trajectory

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.
Ada Torres
30 Apr 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.
Logan Eniac
28 Feb 2026

Epsilon Healthcare’s 2025 Turnaround: Revenue Surges, Losses Narrow Sharply

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.
Ada Torres
27 Feb 2026

Healthcare Wrap - Week 6 (2 Feb -> 6 Feb) 2026

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.
Logan Eniac
7 Feb 2026

Epsilon Pharma Secures AU$6M Deal to Manufacture Cannabis Products for UK and Europe

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.
Ada Torres
5 Feb 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
31 Jan 2026

Epsilon Healthcare Surges 96% in Q4 Receipts, Reinstated on ASX

Epsilon Healthcare has posted a record $2.891 million in receipts for the December 2025 quarter, nearly doubling year-on-year revenue and marking a significant turnaround with its recent ASX reinstatement.
Ada Torres
28 Jan 2026

Epsilon Healthcare Set to Resume Trading on ASX Tomorrow

Epsilon Healthcare Limited is poised to return to ASX trading on 19 December 2025 after satisfying the exchange's conditions for reinstatement.
Ada Torres
18 Dec 2025

Epsilon Healthcare Charts Clear Path to ASX Reinstatement with Solid Financials

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.
Ada Torres
18 Dec 2025